Sales of Teva's ($TEVA) multiple sclerosis drug, Copaxone, are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales. That, in turn, helped profit hit $1.32 per share, passing analysts' estimates. And speaking of that Supreme Court appeal, CEO Erez Vigodman said Thursday that he's optimistic the court will rule in Teva's favor. Report | More